本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
SHANGHAI, Nov. 27, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will hold investor calls on the data results from EVER001 Phase 1b/2a clinical study in primary membranous nephropathy. EVER001 is a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor, and Everest owns the global rights to develop EVER001 for the treatment of renal diseases. The English session of the conference call will be held at 9:00 AM on Dec. 4, 2024 Beijing Time (8:00 PM U.S. Eastern Time on Dec. 3, 2024) and the Mandarin session of the conference call will be held at 10:30 AM Beijing Time on the same day (9:30 PM U.S. Eastern Time on Dec. 3, 2024). The conference calls can be accessed by the following links: For English Session: Time: 9:00 AM Beijing Time, Wednesday, Dec. 4, 2024 (8:00 PM U.S. Eastern Time on Dec. 3, 2024) Pre-Registration Link: https://www.acecamptech.com/eventDetail/60510700 Webcast Link: https://www.acecamptech.com/meeting_live/70512679/774680?event_id=60510700 Alternatively, participants may dial in to the conference call using below dial-in information: United States: +1-646-2543594 (EN)Chinese Mainland: +86-10-58084166 (EN) +86-10-58084199 (CN)Hong Kong, China: +852-30051313 (EN) +852-30051355 (CN)United Kingdom: +44-12-1368-0466 (EN)International: +1-866-6363243 (EN)Password: 842080 For Mandarin Session: Time: 10:30 AM Beijing Time, Wednesday, Dec. 4, 2024 (9:30 PM U.S. Eastern Time on Dec. 3, 2024) Webcast Link: https://s.comein.cn/n3arj55s Alternatively, participants may dial into the conference call using below dial-in information: United States: +1-646-3578788 +1-408-7093255Chinese Mainland: 400-969-8928 400-806-3263Hong Kong, China: +852-301-83602Taiwan, China: +886-226563394 +886-277417882Singapore: +65-64075649 +65-66220840United Kingdom: +44-2070970018International: +86-2362737123Password: 377570 The replay of English session will be available shortly after the call and can be accessed by visiting the Company's website at http://www.everestmedicines.com. About EVER001 EVER001 (previously known as XNW1011) is a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor in development globally for the treatment of renal diseases. BTK is an essential component of the B-cell receptor signaling pathways that regulate the survival, activation, proliferation, and differentiation of B lymphocytes. Targeting BTK with small molecule inhibitors has been demonstrated to be an effective treatment option for B-cell lymphomas and autoimmune diseases. Based in part on results from a completed phase 1 study with healthy subjects conducted by SinoMab in China, EVER001 exhibited high selectivity, excellent pharmacokinetics properties, robust target engagement and a safety profile that supports continued clinical development. Under an exclusive licensing agreement with Evopoint Biosciences and SinoMab BioScience, Everest owns the global rights to develop, produce and commercialize EVER001 for the treatment of renal diseases. About Everest Medicines Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company's core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com. Forward-Looking Statements: This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
CHENGDU, China, Nov. 27, 2024 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization in China from National Medical Products Administration (NMPA) for the first domestically developed trophoblast cell-surface antigen 2 (TROP2)-directed antibody–drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) for adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting). This is the first domestically developed TROP2 ADC approved for marketing in China and the first domestically developed ADC fully approved for marketing in China. The approval is based on the positive results from a randomized, controlled, phase 3 OptiTROP-Breast01 study in adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting). Sac-TMT demonstrated statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) compared to chemotherapy. The results were presented at the special clinical science symposium for next-generation ADCs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2024. Previously, NMPA has accepted two supplemental new drug applications (sNDA) seeking the approvals of sac-TMT monotherapy for the treatment of patients with locally advanced or metastatic EGFR-mutant non-small cell lung cancer (NSCLC) following progression on EGFR-TKI therapy only, or both EGFR-TKI and platinum-based chemotherapy, respectively. Dr. Micheal Ge, CEO of Kelun-Biotech said, "It is a great pleasure to share with you the important milestone moment of the successful approval and launch of sacituzumab tirumotecan in China, which is a significant achievement of Kelun-Biotech's years of deep-rooted source innovation. As the company's first proprietary TROP2 ADC innovative drug, the successful launch of sacituzumab tirumotecan officially opens up a new pattern for the treatment of patients with 2L+ advanced TNBC. We expect that its excellent clinical efficacy and safety results will significantly enhance the clinical benefits and improve the quality of life of patients with advanced TNBC. In the future, we will continue to explore the clinical value of sacituzumab tirumotecan in other indications, maximize the market potential of sacituzumab tirumotecan, and satisfy the clinical needs of patients nationwide." ABOUT MARKET VALUE Breast cancer is a threat to women's lives and health. Among them, triple-negative breast cancer has unique biological behavioral characteristics, and is also known as the "most toxic" breast cancer. 2022 analysis of China's malignant tumor epidemiology data shows that there are 357,000 new cases of breast cancer and 75,000 deaths in Chinese women annually [1]. In the absence of effective therapeutic targets for triple-negative breast cancer, chemotherapy is the most important systemic treatment in the clinic [2], but it often has poor efficacy and high toxicity and side effects, and the prognosis is different from other subtypes of breast cancer [3], it is vital to explore more therapeutic means to improve the clinical benefit. ABOUT sac-TMT Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). ABOUT KELUN-BIOTECH Kelun-Biotech（6990.HK）is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 1 project has been approved for marketing, 3 projects are in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC or novel ADC projects in clinical or preclinical research stage. For more information, please visit https://kelun-biotech.com/. Reference [1].Han, Bingfeng, et al. "Cancer incidence and mortality in China, 2022." Journal of the National Cancer Center 4.1 (2024): 47-53. [2]. [Chinese Society of Clinical Oncology (CSCO) (2024)] Guidelines for the diagnosis and treatment of breast cancer. [3]. https://seer.cancer.gov/statfacts/html/breast-subtypes.html.
Maintained Operational Profitability for the Third Consecutive Quarter Operating Expenses as a Percentage of Revenues Decreased 160 Basis Points YoY Held Positive Operating Cash Flow for Three Consecutive Quarters SHANGHAI, Nov. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Net revenues were RMB3.6 billion (US$513.1 million), remaining relatively flat compared to the same quarter last year. Gross segment profit (1) was RMB 210.6 million (US$ 30.0 million) increased by 10.5% year-over-year. Total operating expenses were RMB208.2 million (US$29.7 million), an improvement of 23.2% compared to RMB271.0 million in the same quarter of last year. As a percentage of net revenues, total operating expenses decreased by 160 basis points to 5.8% from 7.4% in the same quarter of last year, demonstrating continuous improvement in the Company's operational efficiency. Income from operations was RMB2.4 million (US$0.3 million), compared to loss from operations of RMB80.4 million in the same quarter of last year. 111 maintained operational profitability for the third consecutive quarter. Non-GAAP income from operations (2) was RMB7.1 million (US$1.0 million), compared to Non-GAAP loss from operations of RMB54.0 million in the same quarter of last year. Net cash from operating activities was RMB109.9 million (US$15.7 million). The Company has achieved positive operating cash flow for three consecutive quarters. (1) Gross segment profit represents net revenues less cost of goods sold. (2) Non-GAAP income from operations represents income from operations excluding share-based compensation expenses. Mr. Junling Liu, Co-Founder, Chairman, and Chief Executive Officer of 111, commented, "While the macroeconomic environment in China continues to present challenges, we are proud of our ability to maintain operational profitability for the third consecutive quarter. This achievement is a testament to the strength of our business model as a one-stop shopping platform that offers the most comprehensive selection of pharmaceutical products at competitive prices. It also highlights our commitment to operational efficiency across the organization. As a result, income from operations in Q3 reached RMB2.4 million, a significant improvement from an operational loss of RMB80.4 million in the prior year." Mr. Liu added, "We gained greater operational efficiency through diligent cost management, ongoing infrastructure investments, and effective staffing arrangements, all of which has enabled us to navigate an unfavorable consumer spending environment while delivering solid performance results. Operating expenses were 5.8% of revenues, a reduction of 160 basis points compared to the previous year, while non-GAAP operating expenses as a percentage of revenues decreased by 100 basis points to 5.7%. We aim to lead the pharmaceutical e-commerce sector in efficiency and sharpen our competitive advantages. As we scale and optimize operations, we expect further cost savings, which will be reinvested into growth initiatives, including technological advancements, market expansion, and client base growth, driving future profitability." "We are strengthening our core competitiveness in digitalization through advancements across multiple areas, laying a strong foundation for an agile, highly efficient, and customer-centric business that can swiftly adapt to evolving industry needs. Additionally, we've bolstered our supply chain with an expanded transshipment network and new fulfillment centers, further enhancing our service capabilities." "Despite challenges, we are still confident in the long-term opportunities ahead. Our investments in AI and digital technologies are not only providing industry-leading efficiency and reshaping the healthcare value chain, but also positioning us to capture significant shifts in the pharmaceutical industry—particularly the unstoppable trend of digital transformation, the growing demand for out-of-hospital drug distribution, and the expansion of the silver economy. By deepening our partnerships with pharmaceutical companies, expanding our fulfillment network, refining our digital platforms, and prioritizing new growth engines, we are well-positioned to engage more industry stakeholders, meet the needs of a broad customer base, and generate sustained growth." Third Quarter 2024 Financial Results Net revenues were RMB3.6 billion (US$513.1 million), representing a decrease of 1.8% from RMB3.7 billion in the same quarter of last year. (In thousands RMB) For the three months ended September 30, 2023 2024 YoY B2B Net Revenue Product 3,556,749 3,514,298 -1.2 % Service 20,671 21,731 5.1 % Sub-Total 3,577,420 3,536,029 -1.2 % Cost of Products Sold(3) 3,406,320 3,340,998 -1.9 % Segment Profit 171,100 195,031 14.0 % Segment Profit % 4.8 % 5.5 % (In thousands RMB) For the three months ended September 30, 2023 2024 YoY B2C Net Revenue Product 82,538 61,031 -26.1 % Service 5,287 3,615 -31.6 % Sub-Total 87,825 64,646 -26.4 % Cost of Products Sold 68,301 49,061 -28.2 % Segment Profit 19,524 15,585 -20.2 % Segment Profit % 22.2 % 24.1 % (3) For segment reporting purposes, purchase rebates are allocated to the B2B segment and B2C segments primarily based on the amount of cost of products sold for each segment. Cost of products sold does not include other direct costs related to cost of product sales such as shipping and handling expense, payroll and benefits of logistic staff, logistic centers rental expenses and depreciation expenses, which are recorded in the fulfillment expenses. Cost of service revenue is recorded in the operating expense. Operating costs and expenses were RMB3.6 billion (US$512.8 million), representing a decrease of 3.9% from RMB3.7 billion in the same quarter of last year. Cost of products sold was RMB3.4 billion (US$483.1 million), representing a decrease of 2.4% from RMB3.5 billion in the same quarter of last year. Fulfillment expenses were RMB100.0 million (US$14.2 million), representing a decrease of 1.6% from RMB101.6 million in the same quarter of last year. Fulfillment expenses accounted for 2.8% of net revenues this quarter, maintaining the same as last year. Selling and marketing expenses were RMB77.0 million (US$11.0 million), representing a decrease of 19.4% from RMB95.5 million in the same quarter of last year. Excluding the share-based compensation expenses of RMB1.6 million for the quarter and RMB5.1 million for the same quarter last year, respectively, selling and marketing expenses as a percentage of net revenues accounted for 2.1% in the quarter as compared to 2.5% in the same quarter of last year. General and administrative expenses were RMB14.4 million (US$2.0 million), representing a decrease of 68.7% from RMB45.8 million in the same quarter of last year. Excluding the share-based compensation expenses of RMB2.3 million for the quarter and RMB16.8 million for the same quarter last year, respectively, general and administrative expenses as a percentage of net revenues accounted for 0.3% in the quarter as compared to 0.8% in the same quarter of last year. Technology expenses were RMB17.5 million (US$2.5 million), representing a decrease of 30.9% from RMB25.4 million in the same quarter of last year. Excluding the share-based compensation expenses of RMB0.9 million for the quarter and RMB4.5 million for the same quarter last year, respectively, technology expenses as a percentage of net revenues accounted for 0.5% in the quarter as compared to 0.6% in the same quarter of last year. Income from operations was RMB2.4 million (US$0.3 million), compared to loss from operations of RMB80.4 million in the same quarter of last year. Non-GAAP income from operations was RMB7.1 million (US$1.0 million), compared to non-GAAP loss from operations of RMB54.0 million in the same quarter of last year. Net loss was RMB3.5 million (US$0.5 million), representing an improvement of 96% from RMB83.5 million in the same quarter of last year. As a percentage of net revenues, net loss amounted to 0.1% in the quarter, down from 2.3% in the same quarter of last year. Non-GAAP net income (4) was RMB1.3 million (US$0.2 million), compared to non-GAAP net loss of RMB57.1 million in the same quarter of last year. Net loss attributable to ordinary shareholders was RMB17.1 million (US$2.4 million), representing an improvement of 82% from RMB93.3 million in the same quarter of last year. As a percentage of net revenues, net loss attributable to ordinary shareholders accounted for 0.5% in the quarter, down from 2.5% in the same quarter of last year. Non-GAAP net loss attributable to ordinary shareholders (5) was RMB12.4 million (US$1.8 million), representing an improvement of 82% from RMB66.9 million in the same quarter of last year. As a percentage of net revenues, non-GAAP net loss attributable to ordinary shareholders, accounted for 0.3% in the quarter, down from 1.8% in the same quarter of last year. (4) Non-GAAP net income represents net income excluding share-based compensation expenses, net of tax. Considering the impact of accretion of redeemable non-controlling interest for the third quarter 2024, non-GAAP net income is used as a meaningful measurement of the operation performance of the Company. (5) Non-GAAP net loss attributable to ordinary shareholders represents net loss attributable to ordinary shareholders excluding share-based compensation expenses, net of tax. As of September 30, 2024, the Company had cash and cash equivalents, restricted cash and short-term investments of RMB614.4 million (US$87.6 million), compared to RMB673.7 million as of December 31, 2023. To date, the Company has a total outstanding amount of RMB1.1 billion, which has been included in the balances of redeemable non-controlling interests and accrued expenses and other current liabilities, owed to a group of investors of 1 Pharmacy Technology pursuant to their equity investments made in 2020 as previously disclosed. 111 received redemption requests from certain of such investors in accordance with the terms of their initial investments in 1 Pharmacy Technology. Following communication and negotiation, the Company has reached agreements and/or commitment letters with investors representing approximately 90% of the total amount to reschedule the repayments, allowing for phased repayments at extended periods, if the holders exercise their redemption right. The Company has paid a portion of the repurchase funds upon signing of the agreements. Additionally, the Company is in ongoing discussions with investors holding the remaining approximately 10% of the total amount. For more information about the terms of 111's arrangements with these investors, see "Item 5. Operating and Financial Review and Prospects—B. Liquidity and Capital Resources" in the Company's annual report for the fiscal year ended December 31, 2023. Conference Call 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Wednesday, November 27, 2024 (8:30 PM Beijing Time on the same day). Details for the conference call are as follows: Event Title: 111, Inc. Third Quarter 2024 Unaudited Financial ResultsRegistration Link: https://s1.c-conf.com/diamondpass/10042738-te7sgd.html All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a set of participant dial-in numbers, the Direct Event passcode, and a unique Registration ID, which can be used to join the conference call. Please dial in 15 minutes before the call is scheduled to begin and provide the Direct Event passcode and unique Registration ID you have received upon registering to join the call. A telephone replay of the call will be available after the conclusion of the conference call until December 4, 2024 via: China: 4001 209 216United States: +1 855 883 1031International: +61 7 3107 6325Conference ID: 10042738 A live and archived webcast of the conference call will be available on the website at https://edge.media-server.com/mmc/p/3nkscjv6. Use of Non-GAAP Financial Measures In evaluating the business, the Company considers and uses non-GAAP income (loss) from operations, non-GAAP net income (loss), non-GAAP net loss attributable to ordinary shareholders, and non-GAAP loss per ADS, as supplemental measures to review and assess its operating performance. The Company defines non-GAAP income (loss) from operations as income (loss) from operations excluding share-based compensation expenses. The Company defines non-GAAP net income (loss) as net loss excluding share-based compensation expenses, net of tax. The Company defines non-GAAP net loss attributable to ordinary shareholders as net loss attributable to ordinary shareholders excluding share-based compensation expenses, net of tax. The Company defines non-GAAP loss per ADS as net loss attributable to ordinary shareholders per ADS excluding share-based compensation expenses, net of tax per ADS. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP. The Company believes that non-GAAP income (loss) from operations, non-GAAP net income (loss), non-GAAP net loss attributable to ordinary shareholders, and non-GAAP loss per ADS help identify underlying trends in its business that could otherwise be distorted by the effect of certain expenses that it includes in income (loss) from operations and net loss. Share-based compensation expenses is a non-cash expense that varies from period to period. As a result, management excludes the items from its internal operating forecasts and models. Management believes that the adjustments for share-based compensation expenses provide investors with a reasonable basis to measure the company's core operating performance, in a more meaningful comparison with the performance of other companies. The Company believes that non-GAAP income (loss) from operations, non-GAAP net income (loss), non-GAAP net loss attributable to ordinary shareholders, and non-GAAP loss per ADS provide useful information about its operating results, enhances the overall understanding of its past performance and future prospects and allow for greater visibility with respect to key metrics used by the management in their financial and operational decision-making. The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools. One of the key limitations of using non-GAAP income (loss) from operations, non-GAAP net income (loss), non-GAAP net loss attributable to ordinary shareholders, or non-GAAP loss per ADS is that it does not reflect all items of income and expense that affect the Company's operations. Further, the non-GAAP financial measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore their comparability may be limited. The Company compensates for these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP measures, all of which should be considered when evaluating the Company's performance. The Company encourages you to review its financial information in its entirety and not rely on a single financial measure. Reconciliation of the non-GAAP financial measures to the most comparable U.S. GAAP measures is included at the end of this press release. Exchange Rate Information Statement This announcement contains translations of certain RMB amounts into U.S. dollars at specified rates solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB7.0176 to US$1.00, the exchange rate set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System as of September 30, 2024. Forward-Looking Statements This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "confident" and similar statements. Among other things, the Business Outlook and quotations from management in this announcement, as well as 111's strategic and operational plans, contain forward-looking statements. 111 may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control. Forward-looking statements involve inherent risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include, but are not limited to, uncertainties as to the Company's ability comply with extensive and evolving regulatory requirements, its ability to compete effectively in the evolving PRC general health and wellness market, its ability to manage the growth of its business and expansion plans, its ability to achieve or maintain profitability in the future, its ability to control the risks associated with its pharmaceutical retail and wholesale businesses, and the Company's ability to meet the standards necessary to maintain listing of its ADSs on the Nasdaq Global Market, including its ability to cure any non-compliance with Nasdaq's continued listing criteria. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and 111 does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law. About 111, Inc. 111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China. The Company provides consumers with better access to pharmaceutical products and healthcare services directly through its online retail pharmacy, 1 Pharmacy, and indirectly through its offline virtual pharmacy network. The Company also offers online healthcare services through its internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation, electronic prescription service, and patient management service. In addition, the Company's online platform, 1 Medicine, serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. With the largest virtual pharmacy network in China, 111 enables offline pharmacies to better serve their customers with cloud-based services. 111 also provides an omni-channel drug commercialization platform to its strategic partners, which includes services such as digital marketing, patient education, data analytics, and pricing monitoring. For more information on 111, please visit: http://ir.111.com.cn/. For more information, please contact: 111, Inc.Investor RelationsEmail: ir@111.com.cn 111, Inc.Media Relations Email: press@111.com.cnPhone: +86-021-2053 6666 (China) 111, Inc. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except for share and per share data) As of As of December 31, 2023 September 30, 2024 RMB RMB US$ ASSETS Current assets: Cash and cash equivalents 603,523 531,981 75,807 Restricted cash 20,025 32,430 4,621 Short-term investments 50,143 50,000 7,125 Accounts receivable, net 536,823 425,159 60,585 Notes receivable 77,598 80,853 11,521 Inventories 1,419,396 1,532,170 218,332 Prepayments and other current assets 225,823 234,295 33,388 Total current assets 2,933,331 2,886,888 411,379 Property and equipment, net 34,340 25,558 3,642 Intangible assets, net 2,256 1,643 234 Long-term investments 2,000 1,000 142 Other non-current assets 13,310 15,684 2,235 Operating lease right-of-use asset 103,799 98,909 14,094 Total assets 3,089,036 3,029,682 431,726 LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' DEFICIT Current liabilities: Short-term borrowings 338,075 168,517 24,013 Accounts payable 1,588,693 1,912,109 272,474 Accrued expense and other current liabilities 818,295 569,246 81,116 Total current liabilities 2,745,063 2,649,872 377,603 Long-term operating lease liabilities 62,624 63,969 9,116 Other non-current liabilities 5,245 8,331 1,187 Total liabilities 2,812,932 2,722,172 387,906 MEZZANINE EQUITY Redeemable non-controlling interests 870,825 943,774 134,487 SHAREHOLDERS' DEFICIT Ordinary shares Class A 32 33 5 Ordinary shares Class B 25 25 3 Treasury shares (5,887) (5,887) (839) Additional paid-in capital 3,169,114 3,167,794 451,407 Accumulated deficit (3,819,249) (3,864,151) (550,637) Accumulated other comprehensive income 72,514 72,602 10,346 Total shareholders' deficit (583,451) (629,584) (89,715) Non-controlling interest (11,270) (6,680) (952) Total deficit (594,721) (636,264) (90,667) Total liabilities, mezzanine equity and deficit 3,089,036 3,029,682 431,726 111, Inc. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (In thousands, except for share and per share data) For the three months ended September 30, For the nine months ended September 30, 2023 2024 2023 2024 RMB RMB US$ RMB RMB US$ Net revenues 3,665,245 3,600,675 513,092 10,839,503 10,553,474 1,503,858 Operating costs and expenses: Cost of products sold (3,474,621) (3,390,059) (483,080) (10,204,779) (9,926,727) (1,414,547) Fulfillment expenses (101,602) (99,977) (14,247) (299,202) (276,559) (39,409) Selling and marketing expenses (95,523) (76,954) (10,966) (274,880) (237,724) (33,875) General and administrative expenses (45,839) (14,367) (2,047) (126,235) (50,747) (7,231) Technology expenses (25,386) (17,549) (2,501) (75,243) (54,225) (7,727) Other operating (expenses) income, net (2,696) 602 86 (2,723) 1,941 277 Total operating costs and expenses (3,745,667) (3,598,304) (512,755) (10,983,062) (10,544,041) (1,502,512) (Loss) Income from operations (80,422) 2,371 337 (143,559) 9,433 1,346 Interest income 2,362 1,533 218 6,517 5,574 794 Interest expense (5,433) (7,810) (1,113) (14,525) (23,067) (3,287) Foreign exchange gain (loss) 79 642 91 (1,095) 40 6 Other income (loss), net 38 (193) (28) 4,552 (116) (17) Loss before income taxes (83,376) (3,457) (495) (148,110) (8,136) (1,158) Income tax expense (102) (5) (1) (102) (93) (13) Net loss (83,478) (3,462) (496) (148,212) (8,229) (1,171) Net loss attributable to non-controlling interest 4,315 848 121 7,837 (431) (61) Net loss attributable to redeemable non-controlling interest 7,253 438 62 12,529 1,168 166 Adjustment attributable to redeemable non-controlling interest (21,391) (14,931) (2,128) (54,481) (37,410) (5,331) Net loss attributable to ordinary shareholders (93,301) (17,107) (2,441) (182,327) (44,902) (6,397) Other comprehensive loss Unrealized gains of available-for-sale securities, 1,013 (407) (58) 3,936 (753) (107) Realized gains of available-for-sale debt securities (841) 407 58 (3,558) 896 128 Foreign currency translation adjustments (1,690) (1,184) (169) 4,234 (55) (8) Comprehensive loss (94,819) (18,291) (2,610) (177,715) (44,814) (6,384) Loss per ADS: Basic and diluted (1.10) (0.20) (0.02) (2.16) (0.52) (0.08) Weighted average number of shares used in computation of loss per share Basic and diluted 169,088,015 171,938,537 171,938,537 168,179,779 171,526,062 171,526,062 111, Inc. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) For the three months ended September 30, For the nine months ended September 30, 2023 2024 2023 2024 RMB RMB US$ RMB RMB US$ Net cash provided by (used in) operating activities 35,208 109,865 15,656 (250,230) 311,563 44,397 Net cash provided by (used in) investing activities 5,163 49,845 7,103 91,913 (141) (20) Net cash provided by (used in) financing activities 110,452 (110,510) (15,748) 204,230 (370,453) (52,789) Effect of exchange rate changes on cash and cash equivalents, and restricted cash 2,621 (313) (45) 3,514 (106) (15) Net increase (decrease) in cash and cash equivalents, and restricted cash 153,444 48,887 6,966 49,427 (59,137) (8,427) Cash and cash equivalents, and restricted cash at the beginning of the period 612,774 515,524 73,462 716,791 623,548 88,855 Cash and cash equivalents, and restricted cash at the end of the period 766,218 564,411 80,428 766,218 564,411 80,428 111, Inc. Unaudited Reconciliation of GAAP and Non-GAAP Results (In thousands, except for share and per share data) For the three months ended September 30, For the nine months ended September 30, 2023 2024 2023 2024 RMB RMB US$ RMB RMB US$ (Loss) Income from operations (80,422) 2,371 337 (143,559) 9,433 1,346 Add: Share-based compensation expenses 26,402 4,756 678 74,818 15,122 2,155 Non-GAAP (loss) income from operations (54,020) 7,127 1,015 (68,741) 24,555 3,501 Net loss (83,478) (3,462) (496) (148,212) (8,229) (1,171) Add: Share-based compensation expenses, net of tax 26,402 4,756 678 74,818 15,122 2,155 Non-GAAP net (loss) income (57,076) 1,294 182 (73,394) 6,893 984 Net loss attributable to ordinary shareholders (93,301) (17,107) (2,441) (182,327) (44,902) (6,397) Add: Share-based compensation expenses, net of tax 26,402 4,756 678 74,818 15,122 2,155 Non-GAAP net loss attributable to ordinary shareholders (66,899) (12,351) (1,763) (107,509) (29,780) (4,242) Loss per ADS(6): Basic and diluted (1.10) (0.20) (0.02) (2.16) (0.52) (0.08) Add: Share-based compensation expenses per ADS(6), net of tax 0.32 0.06 0.00 0.88 0.18 0.02 Non-GAAP loss per ADS(6) (0.78) (0.14) (0.02) (1.28) (0.34) (0.06) (6) Every one ADS represents two Class A ordinary shares.
GUANGZHOU, China, Nov. 26, 2024 /PRNewswire/ -- VectorBuilder, a global leader in end-to-end gene delivery services, and Sartorius, a leading international partner in life science research and the biopharmaceutical industry, recently announced a strategic cooperation agreement. The collaboration will focus on gene vector and mRNA bioprocess solutions and services, accelerating the development and clinical translation of innovative biopharmaceutical projects. Building on years of successful collaboration, Sartorius and the VectorBuilder have agreed to further expand the scope of their partnership. The new cooperation will cover various areas, such as co-development of innovative downstream processes for cell and gene therapies; further optimization of the development platform and commercial production of GMP-compliant mRNA, plasmid and viral vectors; partnering to support the achievement of sustainability goals; and regular exchange as well as training of talent from both companies. Moreover, VectorBuilder will be a developing partner for applications in the field of the new modalities. "Sartorius is deeply committed to customer-centric innovation, which is the cornerstone of our product development and service provision," said Sarah Wang, Head of Sartorius China. "We anticipate that this strategic partnership will yield innovative solutions aimed at enhancing the efficiency and quality of biomedical enterprises. Together, we aim to support the growth of our global customers and the broader biomedical industry, and to contribute to the advancement of life sciences through transformative processes." "Innovation is in the DNA of VectorBuilder. This agreement with Sartorius allows us to further expand our reach and impact, empowering researchers and pharmaceutical companies worldwide with advanced gene delivery solutions," said Dr. Bruce Lahn, Founder and Chief Scientist of VectorBuilder. "We are excited to combine our expertise to create a more efficient and effective biopharmaceutical ecosystem." "By partnering with VectorBuilder, we look forward to leveraging the expertise of both companies to enable more innovations in downstream processing, further reducing time to market and ultimately saving more people's lives," Michaela Pischke added, Head of the Business Area Separation Technologies. "Congratulations to our China team who have done a great job in laying the groundwork to strengthen this partnership." Both companies are committed to exploring the vast potential of cell and gene therapies and accelerating the translation of research breakthroughs into life-saving treatments. About SartoriusSartorius | Biopharma, Laboratory, Applied & Life Sciences About VectorBuilderwww.vectorbuilder.com
STUTTGART, Germany, Nov. 26, 2024 /PRNewswire/ -- Exyte, a global leader in the design, engineering, and delivery of high-tech facilities, was presented with the Outstanding Supplier Performance Award in Supplier Diversity at the Micron Supplier Day 2024. The event, held in San Francisco, CA, USA, was attended by top-level management of Micron and its suppliers, including Exyte. This award highlights Exyte's commitment to excellence in quality, innovation, and collaboration with Micron, a global leader in memory and storage solutions. Exyte has received Micron's Outstanding Supplier Award in Supplier Diversity. "I am truly grateful and honored to be receiving this award on behalf of Exyte. It is always great to receive such recognition directly from our clients, more so from an industry leader like Micron. I am very proud of our employees involved, that their exceptional hard work and commitment to deliver for Micron are highly appreciated," commented Dr. Wolfgang Büchele, Exyte Group Chairman and CEO, in his award acceptance speech. The Micron Global Supplier Award is an annual accolade that celebrates outstanding supplier performance across twelve categories. The awards are determined through a comprehensive evaluation process that scores suppliers on various criteria. Exyte's long-standing collaboration with Micron stretches back for more than a decade. Exyte has fostered a strong cooperation with Micron through major projects in both Asia and the USA. For over 45 years, Micron's innovative memory solutions have been instrumental to the world's most significant technological advancements. Exyte is privileged to play a role in helping elevate the capabilities of customers such as Micron as Exyte continues with its mission of creating a better future for all, together. "My heartfelt congratulations to all our team members for winning this award. I am extremely thrilled for them as this win is a remarkable testament to the collective effort and dedication they bring to their work at Micron," lauded Mark Garvey, Exyte Executive Board Member and CEO of Global Business Unit Advanced Technology Facilities. "I would also like to thank Micron for their continuous support and in recognizing the contributions of their suppliers. I look forward to reinforcing Exyte's collaboration with Micron in 2025 and beyond," Garvey added. About Exyte Exyte is a global leader in the design, engineering, and delivery of ultra-clean and sustainable facilities for high-tech industries. With cutting-edge expertise developed over more than a century, the company serves clients in the sophisticated markets of semiconductors, battery cells, pharmaceuticals, biotechnology, and data centers. Exyte offers a full range of services from consulting to managing the implementation of turnkey solutions with the highest standards in safety and quality to its customers worldwide. Exyte creates a better future by enabling key industries to enhance the quality of modern life. In 2023, the company generated sales of €7.1 billion with around 9,700 employees worldwide. Contact Samy Abdel AalPublic Relations ManagerMobile: +49 172 840 33 01Phone: +49 711 880 44 696samy.abdelaal@exyte.net www.exyte.net Exyte CEO Wolfgang Büchele receives the award from Fran Dillard, Micron's Chief Diversity Inclusion Officer.
SINGAPORE, Nov. 26, 2024 /PRNewswire/ -- QDX proudly announces that the team led by its co-founder, Associate Professor Giuseppe Barca, has been honoured with the 2024 ACM Gordon Bell Prize, often referred to as the "Nobel Prize of high-performance computing." This accolade recognizes their groundbreaking work in quantum chemistry simulations, which is set to revolutionize QDX's drug discovery technology. The award-winning project, titled "Breaking the Million-Electron and 1 EFLOP/s Barriers: Biomolecular-Scale Ab Initio Molecular Dynamics Using MP2 Potentials," was a collaborative effort involving researchers from the Barca group at the University of Melbourne, the Australian National University, and QDX; along with researchers from Advanced Micro Devices, Inc., and Oak Ridge National Laboratory. Utilizing the Frontier supercomputer, the team achieved quantum-accurate simulations of biological systems at an unprecedented scale, marking a significant milestone in computational chemistry. A/Prof Barca's leadership in this project directly enhances QDX's capabilities in drug discovery. The advanced simulation techniques developed allow for highly precise predictions of molecular behaviour, enabling the design of new therapeutics with greater accuracy and efficiency. "Receiving the Gordon Bell Prize is a tremendous honour," said A/Prof Barca. "This achievement underscores the potential of high-performance computing in transforming drug discovery processes. At QDX, we are committed to leveraging these advancements to accelerate the development of novel therapeutics, ultimately improving patient outcomes." Loong Wang, Co-Founder and CEO of QDX, added, "Giuseppe's recognition with the Gordon Bell Prize is a testament to the innovative spirit at QDX. His work exemplifies our mission to integrate cutting-edge computational techniques into drug discovery, paving the way for more effective treatments. We are excited to see how these advancements will continue to drive our efforts in developing solutions for complex diseases." QDX has already integrated these cutting-edge simulation methods into its platform, collaborating with pharmaceutical companies and tech startups across Australia, Singapore, and the United States. QDX is building on the innovative breakthroughs pioneered by A/Prof Barca and his team, which made this exascale accomplishment possible, to further strengthen and optimize its computational drug discovery pipeline. This includes the development of the world's first in-silico simulation technology capable of leveraging exascale computing for the high-precision design of therapeutics. For more information about QDX and its innovative drug discovery technology, please visit www.qdx.co. About QDX QDX is a drug discovery company specializing in high-performance quantum simulations to accelerate the design of new therapeutics. Founded by experts in life science, computational chemistry, and high-performance computing, QDX collaborates with global partners to develop innovative solutions for complex diseases, aiming to transform the landscape of drug discovery. About the ACM and the Gordon Bell Prize The Association for Computing Machinery (ACM) is the world's leading computing society, dedicated to advancing knowledge and innovation in the field. The ACM Gordon Bell Prize is awarded annually to recognize outstanding achievement in high-performance computing. It is named in honour of Gordon Bell, a pioneer in the field of computer architecture and parallel computing.
Biotechnology
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
